Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.
2.

Are we over-treating with checkpoint inhibitors?

Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S, Corrie P.

Br J Cancer. 2019 Oct;121(8):629-630. doi: 10.1038/s41416-019-0570-y. Epub 2019 Sep 17. No abstract available.

3.

Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

Peach H, Board R, Cook M, Corrie P, Ellis S, Geh J, King P, Laitung G, Larkin J, Marsden J, Middleton M, Moncrieff M, Nathan P, Powell B, Pritchard-Jones R, Rodwell S, Steven N, Lorigan P.

J Plast Reconstr Aesthet Surg. 2020 Jan;73(1):36-42. doi: 10.1016/j.bjps.2019.06.020. Epub 2019 Jun 28.

PMID:
31477493
4.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR.

Ann Oncol. 2019 Dec 1;30(12):2013-2014. doi: 10.1093/annonc/mdz237. No abstract available.

5.

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group.

Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Erratum in: Lancet Oncol. 2019 Apr 2;:.

PMID:
30922733
6.

A sinister black finding in the stomach.

Januszewicz W, Corrie P, Liu H, Chan J, Fitzgerald RC, di Pietro M.

Lancet. 2019 Mar 16;393(10176):1149. doi: 10.1016/S0140-6736(19)30423-4. Epub 2019 Mar 14. No abstract available.

PMID:
30894270
7.

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).

Strauss VY, Shaw R, Virdee PS, Hurt CN, Ward E, Tranter B, Patel N, Bridgewater J, Parsons P, Radhakrishna G, O'Neill E, Sebag-Montefiore D, Hawkins M, Corrie PG, Maughan T, Mukherjee S.

BMC Cancer. 2019 Feb 4;19(1):121. doi: 10.1186/s12885-019-5307-z.

8.

A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).

Corrie PG, Terheyden P, Ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P.

Br J Dermatol. 2019 May;180(5):1254-1255. doi: 10.1111/bjd.17465. Epub 2019 Feb 10. No abstract available.

PMID:
30488430
9.

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR.

Ann Oncol. 2019 Feb 1;30(2):317-324. doi: 10.1093/annonc/mdy500.

10.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

11.

Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.

O'Reilly D, Fou L, Hasler E, Hawkins J, O'Connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, McGeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J.

Pancreatology. 2018 Dec;18(8):962-970. doi: 10.1016/j.pan.2018.09.012. Epub 2018 Sep 28. Review.

PMID:
30292643
12.

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.

Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, Gurnell M, Shaw A, Tischkowitz M, Maher ER, Chatterjee VK, Janowitz T, Mells G, Corrie P, Challis BG.

Semin Oncol. 2018 Jun;45(3):151-155. doi: 10.1053/j.seminoncol.2018.06.001. Epub 2018 Jun 21.

13.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, Barker E, Newton-Bishop J, Middleton MR, Corrie PG.

Br J Cancer. 2018 Oct;119(7):793-800. doi: 10.1038/s41416-018-0179-6. Epub 2018 Jul 23.

14.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators.

Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Erratum in: Ann Oncol. 2019 Dec 1;30(12):2013-2014. Ann Oncol. 2019 Dec;30(12):2013-2014.

15.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

16.

Expert Elicitation of Multinomial Probabilities for Decision-Analytic Modeling: An Application to Rates of Disease Progression in Undiagnosed and Untreated Melanoma.

Wilson ECF, Usher-Smith JA, Emery J, Corrie PG, Walter FM.

Value Health. 2018 Jun;21(6):669-676. doi: 10.1016/j.jval.2017.10.009. Epub 2017 Dec 8.

17.

A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom.

Wilson ECF, Usher-Smith JA, Emery J, Corrie P, Walter FM.

Value Health. 2018 Jun;21(6):658-668. doi: 10.1016/j.jval.2017.11.009. Epub 2018 Apr 11.

18.

HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.

Doherty GJ, Tempero M, Corrie PG.

Future Oncol. 2018 Jan;14(1):13-22. doi: 10.2217/fon-2017-0338. Epub 2017 Oct 23.

PMID:
29235360
19.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

20.

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.

Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, Parkinson CA, Corrie PG.

ESMO Open. 2017 Oct 10;2(4):e000268. doi: 10.1136/esmoopen-2017-000268. eCollection 2017.

21.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP.

Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2.

PMID:
28259610
22.

Genomic analysis and clinical management of adolescent cutaneous melanoma.

Rabbie R, Rashid M, Arance AM, Sánchez M, Tell-Marti G, Potrony M, Conill C, van Doorn R, Dentro S, Gruis NA, Corrie P, Iyer V, Robles-Espinoza CD, Puig-Butille JA, Puig S, Adams DJ.

Pigment Cell Melanoma Res. 2017 May;30(3):307-316. doi: 10.1111/pcmr.12574. Epub 2017 Apr 19.

23.

Lesson of the month 2: Cauda equina in Cushing's syndrome.

Maslin D, Gounaris I, Ng K, Corrie P.

Clin Med (Lond). 2016 Feb;16(1):88-90. doi: 10.7861/clinmedicine.16-1-88.

24.

Withdrawal of anticancer therapy in advanced disease: a systematic literature review.

Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S.

BMC Cancer. 2015 Nov 11;15:892. doi: 10.1186/s12885-015-1862-0. Review.

25.

Evolving treatment options for melanoma brain metastases.

Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S.

Lancet Oncol. 2015 Oct;16(13):e486-97. doi: 10.1016/S1470-2045(15)00141-2. Review.

PMID:
26433822
26.

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B.

Oncology. 2015;89(5):281-7. doi: 10.1159/000439171. Epub 2015 Sep 16.

PMID:
26372905
27.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG.

Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185.

28.

Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists.

Jones C, Clapton G, Zhao Z, Barber B, Saltman D, Corrie P.

Eur J Cancer Care (Engl). 2015 Nov;24(6):867-72. doi: 10.1111/ecc.12359. Epub 2015 Jul 29.

29.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

30.

Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland.

Walter FM, Abel GA, Lyratzopoulos G, Melia J, Greenberg D, Brewster DH, Butler H, Corrie PG, Campbell C.

Cancer Epidemiol. 2015 Aug;39(4):554-61. doi: 10.1016/j.canep.2015.06.006. Epub 2015 Jul 2.

31.

Treatment patterns in advanced melanoma: findings from a survey of European oncologists.

Jones C, Zhao Z, Barber B, Bagijn M, Corrie P, Saltman D.

Eur J Cancer Care (Engl). 2015 Nov;24(6):862-6. doi: 10.1111/ecc.12326. Epub 2015 May 18.

PMID:
25988349
32.

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Welsh SJ, Corrie PG.

Ther Adv Med Oncol. 2015 Mar;7(2):122-36. doi: 10.1177/1758834014566428. Review.

33.

Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.

Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, Jah A.

Medicine (Baltimore). 2015 Feb;94(6):e499. doi: 10.1097/MD.0000000000000499.

34.

Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.

Cook N, Brais R, Qian W, Hak CC, Corrie PG.

J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.

PMID:
25572612
35.

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, Wise A, Suter S, Ciria C, Love S, Collins L, Middleton MR.

Eur J Cancer. 2015 Feb;51(3):359-66. doi: 10.1016/j.ejca.2014.11.018. Epub 2014 Dec 24.

PMID:
25542057
36.

Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.

Sammut SJ, Tomson N, Corrie P.

N Engl J Med. 2014 Sep 25;371(13):1265-7. doi: 10.1056/NEJMc1407683. No abstract available.

PMID:
25251629
37.

Management of melanoma.

Corrie P, Hategan M, Fife K, Parkinson C.

Br Med Bull. 2014 Sep;111(1):149-62. doi: 10.1093/bmb/ldu019. Review.

PMID:
25190764
38.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
39.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

40.

"It can't be very important because it comes and goes"--patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study.

Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S.

BMJ Open. 2014 Feb 18;4(2):e004215. doi: 10.1136/bmjopen-2013-004215.

41.

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong TV, Corrie PG.

Eur J Cancer. 2014 Mar;50(5):902-11. doi: 10.1016/j.ejca.2013.12.011. Epub 2014 Jan 17.

PMID:
24445147
42.

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G.

Cancer Immunol Immunother. 2014 Feb;63(2):175-83. doi: 10.1007/s00262-013-1502-y. Epub 2013 Nov 29.

PMID:
24292263
43.

Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).

Liniker E, Harrison M, Weaver JM, Agrawal N, Chhabra A, Kingshott V, Bailey S, Eisen TG, Corrie PG.

Br J Cancer. 2013 Oct 15;109(8):2051-7. doi: 10.1038/bjc.2013.495. Epub 2013 Sep 24.

44.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A.

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

PMID:
24019551
45.

Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.

Corrie PG, Moody AM, Armstrong G, Nolasco S, Lao-Sirieix SH, Bavister L, Prevost AT, Parker R, Sabes-Figuera R, McCrone P, Balsdon H, McKinnon K, Hounsell A, O'Sullivan B, Barclay S.

Br J Cancer. 2013 Sep 17;109(6):1549-55. doi: 10.1038/bjc.2013.414. Epub 2013 Aug 29.

46.

Inspired to improve outcomes in pancreatic cancer. Interviewed by Natasha Galukande.

Corrie P.

Future Oncol. 2013 Jun;9(6):781-4. doi: 10.2217/fon.13.45. No abstract available.

47.

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Brady J, Corrie P, Chau I, Digumarti R, Adams LM, Botbyl J, Laubscher KH, Midgley RS, Mallath M.

Invest New Drugs. 2013 Oct;31(5):1228-35. doi: 10.1007/s10637-013-9938-7. Epub 2013 Feb 28.

PMID:
23456563
48.

Outcome of second-line chemotherapy for biliary tract cancer.

Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J.

Eur J Cancer. 2013 Apr;49(6):1511. doi: 10.1016/j.ejca.2012.11.024. Epub 2012 Dec 20. No abstract available.

PMID:
23265701
49.

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, Lao-Sirieix S, Parashar D, Ahmad A, Daniel F, Hill M, Wilson G, Blesing C, Moody AM, McAdam K, Osborne M.

Br J Cancer. 2012 Aug 7;107(4):585-7. doi: 10.1038/bjc.2012.318. Epub 2012 Jul 19.

50.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR.

Pancreatology. 2012 Jan-Feb;12(1):8-15. doi: 10.1016/j.pan.2011.12.009. Epub 2011 Dec 31.

PMID:
22487467

Supplemental Content

Loading ...
Support Center